AG˹ٷ

STOCK TITAN

[8-K] Clearwater Analytics Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Form 144 filed for Arteris, Inc. (AIP) discloses that insider Nicholas Hawkins plans to sell 11,276 common shares on 5 Aug 2025 through Morgan Stanley Smith Barney. The shares are valued at $106,558, implying an estimated price of roughly $9.46 each. Arteris has 41.98 million shares outstanding, so the proposed sale equals ~0.03 % of the float.

The filing also details the insider’s trading activity over the prior three months: 60,324 shares have already been sold under a Rule 10b5-1 plan, generating about $488 k in gross proceeds. These prior disposals occurred on 13 separate dates between 8 May 2025 and 1 Aug 2025, with individual block sizes ranging from 438 to 11,000 shares.

All shares being sold were acquired via stock-option exercises on 18 Oct 2021 and paid for in cash. The signer certifies no undisclosed material adverse information. While the absolute number of shares is small relative to Arteris’s capitalization, the steady cadence of insider selling may draw investor attention to management’s sentiment and share-based compensation practices.

Il modulo 144 presentato per Arteris, Inc. (AIP) rivela che l'insider Nicholas Hawkins intende vendere 11.276 azioni ordinarie il 5 agosto 2025 tramite Morgan Stanley Smith Barney. Le azioni sono valutate 106.558 $, con un prezzo stimato di circa 9,46 $ ciascuna. Arteris ha 41,98 milioni di azioni in circolazione, quindi la vendita proposta corrisponde a circa il 0,03% del flottante.

Il documento dettaglia anche l'attività di trading dell'insider negli ultimi tre mesi: sono già state vendute 60.324 azioni nell'ambito di un piano Rule 10b5-1, generando circa 488.000 $ di ricavi lordi. Queste vendite precedenti sono avvenute in 13 date diverse tra l'8 maggio 2025 e il 1° agosto 2025, con blocchi individuali che variano da 438 a 11.000 azioni.

Tutte le azioni vendute sono state acquisite tramite esercizio di opzioni su azioni il 18 ottobre 2021 e pagate in contanti. Il firmatario certifica che non esistono informazioni materiali negative non divulgate. Sebbene il numero assoluto di azioni sia piccolo rispetto alla capitalizzazione di Arteris, la costante frequenza di vendite da parte degli insider potrebbe attirare l'attenzione degli investitori sul sentiment della direzione e sulle pratiche di compensazione basate sulle azioni.

El formulario 144 presentado para Arteris, Inc. (AIP) revela que el insider Nicholas Hawkins planea vender 11,276 acciones ordinarias el 5 de agosto de 2025 a través de Morgan Stanley Smith Barney. Las acciones están valoradas en 106,558 $, lo que implica un precio estimado de aproximadamente 9,46 $ cada una. Arteris tiene 41,98 millones de acciones en circulación, por lo que la venta propuesta equivale a aproximadamente el 0,03% del float.

El documento también detalla la actividad comercial del insider durante los tres meses previos: ya se han vendido 60,324 acciones bajo un plan Rule 10b5-1, generando alrededor de 488.000 $ en ingresos brutos. Estas disposiciones previas ocurrieron en 13 fechas diferentes entre el 8 de mayo de 2025 y el 1 de agosto de 2025, con bloques individuales que varían entre 438 y 11.000 acciones.

Todas las acciones que se venden fueron adquiridas mediante ejercicios de opciones sobre acciones el 18 de octubre de 2021 y pagadas en efectivo. El firmante certifica que no existe información adversa material no divulgada. Aunque el número absoluto de acciones es pequeño en relación con la capitalización de Arteris, la constante frecuencia de ventas por parte del insider podría atraer la atención de los inversores sobre el sentimiento de la dirección y las prácticas de compensación basadas en acciones.

Arteris, Inc. (AIP)� 대� 제출� 144 양식은 내부� Nicholas Hawkins2025� 8� 5�� Morgan Stanley Smith Barney� 통해 11,276 보통�� 매도� 계획임을 밝힙니다. 주식 갶치는 106,558달러�, 주당 � 9.46달러� 추산됩니�. Arteris� 4,198� �갶 발행되어 있어 제안� 매도� 유통 주식� � 0.03%� 해당합니�.

해당 제출서는 또한 내부자의 최근 3개월� 거래 내역� 상세� 기록하고 있습니다: Rule 10b5-1 계획� 따라 이미 60,324�갶 매도되어 � 48� 8� 달러� � 수익� 창출했습니다. � 매도� 2025� 5� 8일부� 8� 1일까지 13차례� 걸쳐 이루어졌으며, 개별 블록 크기� 438주에� 11,000� 사이였습니�.

매도되는 모든 주식은 2021� 10� 18� 주식옵션 행사� 취득했으� 현금으로 지급했습니�. 서명자는 공개되지 않은 중요� 부정적 정보갶 없음� 증명합니�. Arteris� 시갶총액에 비해 주식 수는 적지�, 내부자의 꾸준� 매도 활동은 경영진의 심리와 주식 기반 보상 관행에 대� 투자자의 관심을 불러일으� � 있습니다.

Le formulaire 144 déposé pour Arteris, Inc. (AIP) révèle que l'initié Nicholas Hawkins prévoit de vendre 11 276 actions ordinaires le 5 août 2025 via Morgan Stanley Smith Barney. Les actions sont évaluées à 106 558 $, ce qui implique un prix estimé d'environ 9,46 $ chacune. Arteris compte 41,98 millions d'actions en circulation, la vente proposée représente donc environ 0,03 % du flottant.

Le dépôt détaille également l'activité de trading de l'initié au cours des trois mois précédents : 60 324 actions ont déjà été vendues dans le cadre d'un plan Rule 10b5-1, générant environ 488 000 $ de produit brut. Ces cessions antérieures ont eu lieu à 13 dates distinctes entre le 8 mai 2025 et le 1er août 2025, avec des blocs individuels allant de 438 à 11 000 actions.

Toutes les actions vendues ont été acquises via l'exercice d'options d'achat d'actions le 18 octobre 2021 et payées en espèces. Le signataire certifie qu'aucune information défavorable matérielle non divulguée n'existe. Bien que le nombre absolu d'actions soit faible par rapport à la capitalisation d'Arteris, la fréquence régulière des ventes d'initiés pourrait attirer l'attention des investisseurs sur le sentiment de la direction et les pratiques de rémunération en actions.

Das eingereichte Formular 144 für Arteris, Inc. (AIP) offenbart, dass Insider Nicholas Hawkins plant, am 5. August 2025 11.276 Stammaktien über Morgan Stanley Smith Barney zu verkaufen. Die Aktien sind mit 106.558 $ bewertet, was auf einen geschätzten Preis von etwa 9,46 $ pro Aktie hindeutet. Arteris hat 41,98 Millionen ausstehende Aktien, sodass der vorgeschlagene Verkauf etwa 0,03 % des Streubesitzes entspricht.

Die Einreichung beschreibt auch die Handelsaktivitäten des Insiders in den vorherigen drei Monaten: Bereits 60.324 Aktien wurden im Rahmen eines Rule 10b5-1-Plans verkauft und erzielten etwa 488.000 $ Bruttoerlös. Diese vorherigen Verkäufe erfolgten an 13 verschiedenen Terminen zwischen dem 8. Mai 2025 und dem 1. August 2025, mit einzelnen Blockgrößen von 438 bis 11.000 Aktien.

Alle verkauften Aktien wurden durch Ausübung von Aktienoptionen am 18. Oktober 2021 erworben und bar bezahlt. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen. Obwohl die absolute Anzahl der Aktien im Vergleich zur Marktkapitalisierung von Arteris gering ist, könnte die stetige Verkaufstätigkeit der Insider die Aufmerksamkeit der Investoren auf die Stimmung des Managements und die aktienbasierten Vergütungspraktiken lenken.

Positive
  • Rule 10b5-1 plan mitigates concerns about trading on non-public information
  • Sale size is only ~0.03 % of shares outstanding, posing negligible dilution or market impact
Negative
  • Continued insider selling (>60 k shares in past 3 months plus new 11 k notice) may signal limited insider confidence
  • Aggregate proceeds ~$0.6 M in a short window could pressure sentiment in the absence of offsetting insider buys

Insights

TL;DR: Multiple 10b5-1 sales and new Form 144 indicate ongoing insider monetization, mildly negative for sentiment.

The filing signals continued disposal of shares by Nicholas Hawkins. Although Rule 10b5-1 plans reduce the risk of information asymmetry, the cumulative sale of >60 k shares in three months plus a fresh 11 k-share notice may be interpreted as waning insider confidence or simple diversification. The amount is immaterial to the float, but frequent filings keep insider-selling headlines alive, which can pressure the stock in low-liquidity periods. No red flags regarding undisclosed adverse information are claimed.

TL;DR: Transaction is immaterial to fundamentals; treat as neutral unless insider selling trend accelerates.

At 0.03 % of outstanding shares and ~$0.1 M value, this planned sale will not affect supply-demand dynamics. Arteris trades millions of dollars daily, so execution risk is minimal. Investors should monitor if other executives follow suit or if Hawkins’s remaining holdings shrink materially. Absent macro context or earnings data, the event is not impactful to valuation models but could weigh on short-term sentiment.

Il modulo 144 presentato per Arteris, Inc. (AIP) rivela che l'insider Nicholas Hawkins intende vendere 11.276 azioni ordinarie il 5 agosto 2025 tramite Morgan Stanley Smith Barney. Le azioni sono valutate 106.558 $, con un prezzo stimato di circa 9,46 $ ciascuna. Arteris ha 41,98 milioni di azioni in circolazione, quindi la vendita proposta corrisponde a circa il 0,03% del flottante.

Il documento dettaglia anche l'attività di trading dell'insider negli ultimi tre mesi: sono già state vendute 60.324 azioni nell'ambito di un piano Rule 10b5-1, generando circa 488.000 $ di ricavi lordi. Queste vendite precedenti sono avvenute in 13 date diverse tra l'8 maggio 2025 e il 1° agosto 2025, con blocchi individuali che variano da 438 a 11.000 azioni.

Tutte le azioni vendute sono state acquisite tramite esercizio di opzioni su azioni il 18 ottobre 2021 e pagate in contanti. Il firmatario certifica che non esistono informazioni materiali negative non divulgate. Sebbene il numero assoluto di azioni sia piccolo rispetto alla capitalizzazione di Arteris, la costante frequenza di vendite da parte degli insider potrebbe attirare l'attenzione degli investitori sul sentiment della direzione e sulle pratiche di compensazione basate sulle azioni.

El formulario 144 presentado para Arteris, Inc. (AIP) revela que el insider Nicholas Hawkins planea vender 11,276 acciones ordinarias el 5 de agosto de 2025 a través de Morgan Stanley Smith Barney. Las acciones están valoradas en 106,558 $, lo que implica un precio estimado de aproximadamente 9,46 $ cada una. Arteris tiene 41,98 millones de acciones en circulación, por lo que la venta propuesta equivale a aproximadamente el 0,03% del float.

El documento también detalla la actividad comercial del insider durante los tres meses previos: ya se han vendido 60,324 acciones bajo un plan Rule 10b5-1, generando alrededor de 488.000 $ en ingresos brutos. Estas disposiciones previas ocurrieron en 13 fechas diferentes entre el 8 de mayo de 2025 y el 1 de agosto de 2025, con bloques individuales que varían entre 438 y 11.000 acciones.

Todas las acciones que se venden fueron adquiridas mediante ejercicios de opciones sobre acciones el 18 de octubre de 2021 y pagadas en efectivo. El firmante certifica que no existe información adversa material no divulgada. Aunque el número absoluto de acciones es pequeño en relación con la capitalización de Arteris, la constante frecuencia de ventas por parte del insider podría atraer la atención de los inversores sobre el sentimiento de la dirección y las prácticas de compensación basadas en acciones.

Arteris, Inc. (AIP)� 대� 제출� 144 양식은 내부� Nicholas Hawkins2025� 8� 5�� Morgan Stanley Smith Barney� 통해 11,276 보통�� 매도� 계획임을 밝힙니다. 주식 갶치는 106,558달러�, 주당 � 9.46달러� 추산됩니�. Arteris� 4,198� �갶 발행되어 있어 제안� 매도� 유통 주식� � 0.03%� 해당합니�.

해당 제출서는 또한 내부자의 최근 3개월� 거래 내역� 상세� 기록하고 있습니다: Rule 10b5-1 계획� 따라 이미 60,324�갶 매도되어 � 48� 8� 달러� � 수익� 창출했습니다. � 매도� 2025� 5� 8일부� 8� 1일까지 13차례� 걸쳐 이루어졌으며, 개별 블록 크기� 438주에� 11,000� 사이였습니�.

매도되는 모든 주식은 2021� 10� 18� 주식옵션 행사� 취득했으� 현금으로 지급했습니�. 서명자는 공개되지 않은 중요� 부정적 정보갶 없음� 증명합니�. Arteris� 시갶총액에 비해 주식 수는 적지�, 내부자의 꾸준� 매도 활동은 경영진의 심리와 주식 기반 보상 관행에 대� 투자자의 관심을 불러일으� � 있습니다.

Le formulaire 144 déposé pour Arteris, Inc. (AIP) révèle que l'initié Nicholas Hawkins prévoit de vendre 11 276 actions ordinaires le 5 août 2025 via Morgan Stanley Smith Barney. Les actions sont évaluées à 106 558 $, ce qui implique un prix estimé d'environ 9,46 $ chacune. Arteris compte 41,98 millions d'actions en circulation, la vente proposée représente donc environ 0,03 % du flottant.

Le dépôt détaille également l'activité de trading de l'initié au cours des trois mois précédents : 60 324 actions ont déjà été vendues dans le cadre d'un plan Rule 10b5-1, générant environ 488 000 $ de produit brut. Ces cessions antérieures ont eu lieu à 13 dates distinctes entre le 8 mai 2025 et le 1er août 2025, avec des blocs individuels allant de 438 à 11 000 actions.

Toutes les actions vendues ont été acquises via l'exercice d'options d'achat d'actions le 18 octobre 2021 et payées en espèces. Le signataire certifie qu'aucune information défavorable matérielle non divulguée n'existe. Bien que le nombre absolu d'actions soit faible par rapport à la capitalisation d'Arteris, la fréquence régulière des ventes d'initiés pourrait attirer l'attention des investisseurs sur le sentiment de la direction et les pratiques de rémunération en actions.

Das eingereichte Formular 144 für Arteris, Inc. (AIP) offenbart, dass Insider Nicholas Hawkins plant, am 5. August 2025 11.276 Stammaktien über Morgan Stanley Smith Barney zu verkaufen. Die Aktien sind mit 106.558 $ bewertet, was auf einen geschätzten Preis von etwa 9,46 $ pro Aktie hindeutet. Arteris hat 41,98 Millionen ausstehende Aktien, sodass der vorgeschlagene Verkauf etwa 0,03 % des Streubesitzes entspricht.

Die Einreichung beschreibt auch die Handelsaktivitäten des Insiders in den vorherigen drei Monaten: Bereits 60.324 Aktien wurden im Rahmen eines Rule 10b5-1-Plans verkauft und erzielten etwa 488.000 $ Bruttoerlös. Diese vorherigen Verkäufe erfolgten an 13 verschiedenen Terminen zwischen dem 8. Mai 2025 und dem 1. August 2025, mit einzelnen Blockgrößen von 438 bis 11.000 Aktien.

Alle verkauften Aktien wurden durch Ausübung von Aktienoptionen am 18. Oktober 2021 erworben und bar bezahlt. Der Unterzeichner bestätigt, dass keine nicht offengelegten wesentlichen negativen Informationen vorliegen. Obwohl die absolute Anzahl der Aktien im Vergleich zur Marktkapitalisierung von Arteris gering ist, könnte die stetige Verkaufstätigkeit der Insider die Aufmerksamkeit der Investoren auf die Stimmung des Managements und die aktienbasierten Vergütungspraktiken lenken.

0001866368false00018663682025-07-312025-07-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_____________________________________________________
FORM 8-K
_____________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 31, 2025
_____________________________________________________
Clearwater Analytics Holdings, Inc.
(Exact name of Registrant as Specified in Its Charter)
_____________________________________________________
Delaware001-4083887-1043711
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
777 W. Main Street
Suite 900
Boise, Idaho
83702
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 208 433-1200
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
_____________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Class A common stock, par value $0.001 per shareCWANNew York Stock Exchange LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 31, 2025, the Board of Directors (the “Board”) of Clearwater Analytics Holdings, Inc. (the “Company”) appointed Bas NieuweWeme to the Board, effective immediately. Mr. Bas NieuweWeme will serve as a Class I director with a term expiring at the Company’s Annual Meeting of Stockholders in 2028.

For serving on the Board, Mr. NieuweWeme will be eligible to receive an annualized cash retainer equal to $40,000 per calendar year. For his initial year of service on the Board, Mr. NieuweWeme will receive a grant of restricted stock units with an equivalent value of $350,000, with the number of restricted stock units calculated by dividing $350,000 by the ten trading-day average closing share price leading up to the day of the grant, vesting in three equal installments on each of the first, second and third anniversaries of the day of the grant, subject to Mr. NieuweWeme’s continued service through each applicable vesting date. Mr. NieuweWeme will also be eligible for an annual grant of restricted stock units with an equivalent value of $200,000, with the number of restricted stock units calculated by dividing $200,000 by the ten trading-day average closing share price leading up to the day of the grant.

Mr. NieuweWeme, 53, has over 25 years of executive leadership experience in the asset management industry and is currently a Senior Advisor at Boston Consulting Group, which he joined in June 2025. Mr. NieuweWeme has also been the team manager for the Dutch National Men’s Hockey Team since November 2024. Previously, Mr. NieuweWeme was the Chief Executive Officer of Aegon Asset Management and a member of the Aegon Ltd. Executive Committee between 2019 to 2024. Mr. NieuweWeme also previously served as a Non-Executive Director and Vice Chairman of the Supervisory Board of La Banque Postale Asset Management from 2019 to 2024 and as a member of the Board of Directors of Aegon Industrial Fund Management Company Limited from 2019 to 2024. Mr. NieuweWeme holds a law degree from the University of Amsterdam School of Law with a specialization in tax law and an Executive MBA from the New York University Stern School of Business.

In connection with Mr. NieuweWeme’s appointment to the Board, the Company has entered into an indemnification agreement with Mr. NieuweWeme in substantially the same form as the Company has entered into with each of the Company’s existing directors and as previously disclosed in the Company’s public filings.

The Board has determined that Mr. NieuweWeme is independent under the applicable standards of the New York Stock Exchange. There were no arrangements or understandings between Mr. NieuweWeme and any other persons pursuant to which he was selected as a director. In addition, Mr. NieuweWeme is not a party to any transaction, or any proposed transaction, required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Item 7.01 Regulation FD Disclosure.

On August 5, 2025, the Company issued a press release announcing the appointment of Mr. NieuweWeme to the Board. The press release also announces the appointment of Dr. Mukesh Aghi, who was elected as a Class I director by the Company’s stockholders at the Company’s 2025 Annual Meeting of Stockholders. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.
(d):The following exhibits are being filed herewith:
Exhibit NumberDescription
99.1
Press release entitled “Clearwater Analytics Announces New Board members to Accelerate International Growth and Innovation” dated August 5, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Clearwater Analytics Holdings, Inc.
Date:August 5, 2025By:/s/ Alphonse Valbrune
Alphonse Valbrune, Chief Legal Officer & Corporate Secretary

FAQ

How many Arteris (AIP) shares are planned for sale in this Form 144?

The filing covers 11,276 common shares scheduled for sale on 5 Aug 2025.

What is the estimated value of the planned insider sale?

At an implied price of ~$9.46, the sale is valued at about $106,558.

How much has the insider already sold in the past 3 months?

Nicholas Hawkins sold 60,324 shares between 8 May 2025 and 1 Aug 2025, raising roughly $488 k.

Does the sale rely on a Rule 10b5-1 trading plan?

Yes. The prior sales and the new notice reference a 10b5-1 plan for pre-arranged trades.

What percentage of Arteris’s outstanding shares does the new sale represent?

Approximately 0.03 % of the 41.98 million shares outstanding.

Were the shares purchased or option-derived?

All shares were acquired through stock-option exercises on 18 Oct 2021 and paid for in cash.
Clearwater Analytics Hldgs Inc

NYSE:CWAN

CWAN Rankings

CWAN Latest News

CWAN Latest SEC Filings

CWAN Stock Data

5.52B
256.47M
0.91%
91.66%
4.98%
Software - Application
Services-prepackaged Software
United States
BOISE